The Q3FY19 standalone operational performance was in line with Idirect estimates while net profit was lower mainly due to higher-thanexpected interest cost and depreciation Revenues grew 14.4% YoY to | 2169 crore (I-direct estimate: | 2145.8 crore) due to 13.9% growth in pharmacy to | 1011.9 crore (Idirect estimate: | 1043.2 crore) and 14.8% YoY growth in healthcare business to | 1157.3 crore (I-direct estimate: | 1102.8 crore) EBITDA margins improved 68 bps YoY to 12.3% (I-direct estimate: 12.6%) mainly due to lower other expenditure. EBITDA grew 21.1% YoY at | 267.9 crore (I-direct estimate: | 271.0 crore) Net profit grew 28.9% to | 86.9 crore (I-direct estimate: | 93.3 crore)...